Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness: A Double-Blind, Randomized, Parallel Group, Dose-Ranging Study

Journal of Pain and Symptom Management

Volumn 35, Issue 5, 2008, Pages 458-468

  Portenoy, Russell K ^a   Thomas, Jay ^b   Moehl Boatwright, Michele L ^c   Tran, Diep ^d   Galasso, Frank L ^d   Stambler, Nancy ^d   Von Gunten, Charles F ^b   Israel, Robert J ^d  

^a BETH ISRAEL MEDICAL CENTER   (United States)

^b San Diego Hospice and Palliative Care   (United States)

^c Lifepath Hospice and Palliative Care   (United States)

^d A Subsidiary of Lantheus Holdings   (United States)

Author keywords

advanced illness; clinical trial; Constipation; dose ranging; gastrointestinal side effects; methylnaltrexone; opioid induced; peripheral opioid antagonist; subcutaneous

Indexed keywords

17 METHYLNALTREXONE; EMOLLIENT AGENT; LAXATIVE; OPIATE; OSMOTIC AGENT;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ADVANCED CANCER; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FLATULENCE; GASTROINTESTINAL SYMPTOM; HUMAN; MALE; MULTICENTER STUDY; NAUSEA; PAIN; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; RESTLESSNESS; RHINORRHEA; SICKLE CELL ANEMIA; SIDE EFFECT; STRUCTURED QUESTIONNAIRE; SWEATING; SYNCOPE; TREATMENT OUTCOME; TREMOR; UNSPECIFIED SIDE EFFECT; URINE RETENTION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; NEOPLASMS; PAIN; PAIN MEASUREMENT; QUATERNARY AMMONIUM COMPOUNDS; TERMINAL CARE;

EID: 42649091132     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2007.12.005     Document Type: Article

References (18)

1. World Health Organization. Cancer pain relief (1986), World Health Organization, Geneva
2. Kalso E., Allan L., Dellemijn P.L., et al. Recommendations for using opioids in chronic non-cancer pain. Eur J Pain 7 (2003) 381-386
3. Fine P., and Portenoy R.K. Opioid analgesia (2004), McGraw Hill, New York, NY
4. Meuser T., Pietruck C., Radbruch L., et al. Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology. Pain 93 (2001) 247-257
5. Kalso E., Edwards J.E., Moore R.A., and McQuay H.J. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain 112 (2004) 372-380
6. Sykes N.P. The relationship between opioid use and laxative use in terminally ill cancer patients. Palliat Med 12 (1998) 375-382
7. Derby S., and Portenoy R.K. Assessment and management of opioid-induced constipation. In: Portenoy R.K., and Bruera E. (Eds). Topics in palliative care (1997), Oxford University Press, New York, NY 95-112
8. Sykes N.P. An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliat Med 10 (1996) 134-144
9. Brown D.R., and Goldberg L.I. The use of quaternary narcotic antagonists in opiate research. Neuropharmacology 24 (1985) 181-191
10. Russell J., Bass P., Goldberg L.I., Schuster C.R., and Merz H. Antagonism of gut, but not central effects of morphine with quaternary narcotic antagonists. Eur J Pharmacol 78 (1982) 255-261
11. Manara L., Bianchi G., Ferretti P., and Tavani A. Inhibition of gastrointestinal transit by morphine in rats results primarily from direct drug action on gut opioid sites. J Pharmacol Exp Ther 237 (1986) 945-949
12. Tavani A., Bianchi G., Ferretti P., and Manara L. Morphine is most effective on gastrointestinal propulsion in rats by intraperitoneal route: evidence for local action. Life Sci 27 (1980) 2211-2217
13. Yuan C.S., Foss J.F., O'Connor M., et al. Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: a double-blind, randomized placebo-controlled trial. Clin Pharmacol Ther 59 (1996) 469-475
14. Yuan C.S., Foss J.F., O'Connor M., et al. Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized control trial. JAMA 283 (2000) 367-372
15. Yuan C.S., Wei G., Foss J.F., et al. Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial. J Pharmacol Exp Ther 300 (2002) 118-123
16. Himmelsbach C.K. The morphine abstinence syndrome, its nature and treatment. Ann Intern Med 15 (1941) 829-839
17. Paulson D.M., Kennedy D.T., Donovick R.A., et al. Alvimopan: an oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction-a 21-day treatment-randomized clinical trial. J Pain 6 (2005) 184-192
18. Culpepper-Morgan J.A., Inturrisi C.E., Portenoy R.K., et al. Treatment of opioid-induced constipation with oral naloxone: a pilot study. Clin Pharm Ther 52 (1992) 90-95